Working... Menu

A Brief Study To Evaluate The Safety, Tolerability, And Blood Levels Of Multiple Doses Of PF-044467943 Or Placebo In Combination With Donepezil In Subjects With Mild To Moderate Alzheimer's Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00988598
Recruitment Status : Completed
First Posted : October 2, 2009
Last Update Posted : August 9, 2010
Information provided by:

Brief Summary:
The purpose of the study is to evaluate the safety of PF-04447943 when given in combination with donepezil in subjects who have Alzheimer's Disease. The study will also evaluate the absorption and distribution of both PF-04447943 and donepezil.

Condition or disease Intervention/treatment Phase
Alzheimer's Disease Drug: PF-04447943 Drug: Placebo Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase 1, Double-Blind, Placebo-Controlled, Sponsor Open, Randomized, Multiple Dose Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-04447943 In Mild To Moderate Alzheimer's Disease Subjects On Stable Donepezil Therapy
Study Start Date : October 2009
Actual Primary Completion Date : July 2010
Actual Study Completion Date : July 2010

Arm Intervention/treatment
Active Comparator: PF-04447943 Drug: PF-04447943
25 mg of PF-04447943 orally every 12 hours for 7 days

Placebo Comparator: Placebo Drug: Placebo
25 mg matching placebo to PF-04447943 orally every 12 hours for 7 days

Primary Outcome Measures :
  1. vital signs [ Time Frame: screening, day 0-day 7, day 10 ]
  2. ECGs [ Time Frame: screening, day 0, 1, 2, 3, 4, 7, and 10 ]
  3. Physical and Neurological examinations [ Time Frame: screening, days 0, 4, and 10 ]
  4. Laboratory tests [ Time Frame: Screening, days 0, 1, 4, 7, and 10 ]
  5. adverse events [ Time Frame: screening through study completion ]

Secondary Outcome Measures :
  1. Plasma concentrations of PF 04447943 over time [ Time Frame: Days 1 and 7 ]
  2. Plasma concentrations of donepezil over time [ Time Frame: days 0 and 7 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   55 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects must have Alzheimer's dementia with a Mini Mental State Examination score between 18-26, inclusive.
  • Subjects must have a reliable caregiver.
  • Subjects must be on Aricept
  • Memantine is allowed if subjects are on a stable dose
  • Subjects must be in reasonably good health, based on medical history, physical examination, vital signs, and ECG, with no serious or unstable disease within the past 3 months.

Exclusion Criteria:

  • Subjects with clinically significant heart disease cannot participate.
  • Subjects with a past or current history of seizures cannot participate.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00988598

Layout table for location information
United States, California
Pfizer Investigational Site
Glendale, California, United States, 91206
United States, Florida
Pfizer Investigational Site
Gainesville, Florida, United States, 32608
Pfizer Investigational Site
Hallandale Beach, Florida, United States, 33009
Sponsors and Collaborators
Layout table for investigator information
Study Director: Pfizer Call Center Pfizer

Additional Information:
Layout table for additonal information
Responsible Party: Director, Clinical Trial Disclosure Group, Pfizer, Inc. Identifier: NCT00988598     History of Changes
Other Study ID Numbers: B0401008
First Posted: October 2, 2009    Key Record Dates
Last Update Posted: August 9, 2010
Last Verified: August 2010

Keywords provided by Pfizer:
phase 1 Alzheimer's disease donepezil

Additional relevant MeSH terms:
Layout table for MeSH terms
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders
Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Nootropic Agents